ENGAGE AF: Effective anticoagulation with factor Xa in next generation treatment of atrial fibrillation.

Lack of reversibility for NOACs. Glob Cardiol Sci Pract (2014) 0.82

RE-ALIGN: First trial of novel oral anticoagulant in patients with mechanical heart valves - The search continues. Glob Cardiol Sci Pract (2014) 0.82

Diabetes and silent atrial fibrillation: A dangerous liaison? Glob Cardiol Sci Pract (2014) 0.75

Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99

Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50

Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet (2013) 12.44

2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J (2012) 12.36

Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2013) 7.70

Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 5.27

Managing atrial fibrillation in the global community: The European perspective. Glob Cardiol Sci Pract (2013) 1.04

Model of reentrant ventricular tachycardia based on infarct border zone geometry predicts reentrant circuit features as determined by activation mapping. Heart Rhythm (2007) 1.76

Detection of the diastolic pathway, circuit morphology, and inducibility of human postinfarction ventricular tachycardia from mapping in sinus rhythm. Heart Rhythm (2008) 1.63

Localisation of SCN10A gene product Na(v)1.8 and novel pain-related ion channels in human heart. Int Heart J (2011) 1.10

Adrenergic regulation of a key cardiac potassium channel can contribute to atrial fibrillation: evidence from an I Ks transgenic mouse. J Physiol (2007) 1.10

Comparison of connexin expression patterns in the developing mouse heart and human foetal heart. Mol Cell Biochem (2003) 1.09

Managing atrial fibrillation in the global community: The European perspective. Glob Cardiol Sci Pract (2013) 1.04

A multi-purpose spiral high-density mapping catheter: initial clinical experience in complex atrial arrhythmias. J Interv Card Electrophysiol (2011) 0.83

RAAFT-2: Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation. Glob Cardiol Sci Pract (2014) 0.83

Response to 'Lack of reversibility for NOACs'. Glob Cardiol Sci Pract (2014) 0.82

Short-term pacing in the mouse alters cardiac expression of connexin43. BMC Physiol (2008) 0.82

Benefits of a quadripolar left ventricular lead in patients undergoing cardiac resynchronization therapy with underlying myocardial scar. Pacing Clin Electrophysiol (2011) 0.80

Decreased connexin43 expression in the mouse heart potentiates pacing-induced remodeling of repolarizing currents. Am J Physiol Heart Circ Physiol (2008) 0.79

The Dabigatran debate. Glob Cardiol Sci Pract (2014) 0.75